Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia

References

• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014;10:425-48
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015;72:1172-81
   PubMed Web of Science ®Google Scholar
• Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013;170:324-33
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012;25:83-8
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010;24(4 Suppl):17-25
   PubMed Web of Science ®Google Scholar
• Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011;168:193-201
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Torniainen M, et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173:600-6
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13
   PubMed Web of Science ®Google Scholar
• Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2010;6:561-72
   PubMed Web of Science ®Google Scholar
• Prescribing Information for Invega Sustenna (paliperidone palmitate) extended release injectable. 2015. Available at: http://www.invegasustenna.com/important-product-information Accessed, January 2016
   Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-17
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose–response study. Int Clin Psychopharmacol 2010;25:247-56
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-44
   PubMed Web of Science ®Google Scholar
• Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1002-8
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Takahashi N, Takahashi M, Saito T, et al. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat 2013;8:1889-98
   PubMed Web of Science ®Google Scholar
• Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022-31
   PubMed Web of Science ®Google Scholar
• Morrato EH, Parks J, Campagna EJ, et al. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. J Comp Eff Res 2015;4:89-99
   PubMed Web of Science ®Google Scholar
• Takahashi N, Takahashi M, Saito T, et al. A long-term, open-label study of paliperidone palmitate in patients with schizophrenia. Post N Med 2013;22:2393-412
   Google Scholar
• Mori K, Watanabe M, Horiuchi N, et al. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety. Clin J Gastroenterol 2014;7:103-7
   PubMedGoogle Scholar
• Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death, European Society of Cardiology. Europace 2002;4:3-18
   PubMed Web of Science ®Google Scholar
• Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12
   PubMed Web of Science ®Google Scholar
• Ringback Weitoft G, Berglund M, Lindstrom EA, et al. Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden – a register-based study. Pharmacoepidemiol Drug Saf 2014;23:290-8
   PubMed Web of Science ®Google Scholar
• Mann RD, Andrews EB. Pharmacovigilance, 2nd edn. Chichester, UK: John Wiley & Sons, 2006
   Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29:385-96
   PubMed Web of Science ®Google Scholar
• Yamada T, Watanabe Y, Kusama M, et al. Factors associated with spontaneous reporting of adverse drug reactions in Japan. Pharmacoepidemiol Drug Saf 2013;22:468-76
   PubMed Web of Science ®Google Scholar
• Matsuda S, Aoki K, Kawamata T, et al. Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS One 2015;10:e0126413
   PubMed Web of Science ®Google Scholar
• Maeda R. JADER from pharmacovigilance point of view [in Japanese]. Jpn J Pharmacoepidemiol 2014;19:6
   Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-17
   PubMed Web of Science ®Google Scholar
• Talaslahti T, Alanen HM, Hakko H, et al. Mortality and causes of death in older patients with schizophrenia. Int J Geriatr Psychiatry 2012;27:1131-7
   PubMed Web of Science ®Google Scholar
• Fujii Y. [What lessons should we learn from the death of patients on xeplion?]. Seishin Shinkeigaku Zasshi 2015;117:132-45
   PubMedGoogle Scholar
• Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993;163:183-9
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough D, Karcher K, et al. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. J Clin Psychopharmacol 2013;33:157-61
   PubMed Web of Science ®Google Scholar
• Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004;58:178-83
   PubMed Web of Science ®Google Scholar
• Xiang YT, Wang CY, Si TM, et al. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001–2009). Pharmacopsychiatry 2012;45:7-12
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
   PubMed Web of Science ®Google Scholar
• Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-7
   PubMed Web of Science ®Google Scholar
• Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:6
   Web of Science ®Google Scholar
• Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9
   PubMed Web of Science ®Google Scholar
• Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry 2005;66:1386-91
   PubMed Web of Science ®Google Scholar
• Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Katsuki A, et al. Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. Int J Psychiatry Clin Pract 2012;16:138-42
   PubMed Web of Science ®Google Scholar